Yubo International Biotech Ltd (YBGJ) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Yubo International Biotech Ltd (YBGJ) stock forecast summary
On Oct. 14, 2026, YBGJ is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for YBGJ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, YBGJ included.
Follow YBGJ freeYBGJ price chart and AI forecast
How YBGJ ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Yubo International Biotech Ltd (YBGJ) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | YBGJ | Rank |
|---|---|---|
| EPS | $-0.01 | – |
Profitability & Margins
| Metric | YBGJ | Rank |
|---|---|---|
| ROA | -87.6% | 22/24 |
| ROIC | 43.9% | 1/23 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | YBGJ | Rank |
|---|---|---|
| Current Ratio | 0.18x | 29/30 |
| Quick Ratio | 0.17x | 28/29 |
| Interest Coverage | 7298.4x | 1/30 |
| Working Capital | -$3M | 28/29 |
Cash Flow
| Metric | YBGJ | Rank |
|---|---|---|
| Operating Cash Flow | -$780K | 13/30 |
Operational Efficiency
| Metric | YBGJ | Rank |
|---|---|---|
| Asset Turnover | 0.01x | 19/19 |
| Receivables Turnover | 0.1x | 20/20 |
| Inventory Turnover | 0.2x | 27/27 |
| Fixed Assets Turnover | 0.7x | 20/20 |
| Days Sales Outstanding | 4079 days | 1/20 |
| Days Inventory | 2162 days | 1/27 |
| Payables Period | 113947 days | 1/24 |
| Cash Conversion Cycle | -107706 days | 19/19 |
Income Statement
| Metric | YBGJ | Rank |
|---|---|---|
| Total Revenue | $0.00M | 19/19 |
| Operating Income | $0.00M | 10/30 |
| Net Income | $0.00M | 11/24 |
| Cost of Goods Sold | $0.00M | 27/27 |
Dividend & Shareholder Information
| Metric | YBGJ | Rank |
|---|---|---|
| EPS Growth | -192.3% | 7/7 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $580K | |
| Cash & Short-term Investments | $10K | |
| Accounts Receivable | $140K | |
| Inventory | $20K | |
| Total Liabilities | $5M | |
| Short-term Debt | $2M |
YBGJ quarterly financials and insider trading
Yubo International Biotech Ltd (YBGJ) industry peers
Companies classified under the same SEC industry code as Yubo International Biotech Ltd (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $323M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| VANI Vivani Medical, Inc. | ▶ | $104M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $77M |
| OM Outset Medical, Inc. | ▲ | $77M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| POSC Positron Corp | ▲ | $53M |
| VASO Vaso Corp | ▲ | $51M |
| POCI Precision Optics Corporation, Inc. | ▲ | $48M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| ITOC Itonic Holdings Ltd | ▼ | $29M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
Where YBGJ sits on the market map
Yubo International Biotech Ltd (YBGJ) stock news
Loading...
Yubo International Biotech Ltd (YBGJ) stock forecast FAQ
What is the Yubo International Biotech Ltd (YBGJ) stock forecast?
On Oct. 14, 2026, YBGJ is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Yubo International Biotech Ltd stock predictions?
A per-ticker accuracy statistic for YBGJ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Yubo International Biotech Ltd forecasts updated?
Yubo International Biotech Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Yubo International Biotech Ltd's industry peers?
32 issuers in our coverage, YBGJ included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.